A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients

Treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor used for treating non-small-cell lung cancer (NSCLC) and other cancers, is frequently associated with adverse events (AE). We present a modeling and simulation framework for the most common erlotinib-induced AE,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:AAPS J
Egile Nagusiak: Suleiman, Ahmed Abbas, Frechen, Sebastian, Scheffler, Matthias, Zander, Thomas, Nogova, Lucia, Kocher, Martin, Jaehde, Ulrich, Wolf, Jürgen, Fuhr, Uwe
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2015
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4627460/
https://ncbi.nlm.nih.gov/pubmed/26286677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1208/s12248-015-9815-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak